- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
Tyra Biosciences is a biotechnology business based in the US. Tyra Biosciences shares (TYRA) are listed on the NASDAQ and all prices are listed in US Dollars. Tyra Biosciences employs 25 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$13.18|
|52-week range||$4.93 - $13.78|
|50-day moving average||$7.38|
|200-day moving average||$7.95|
|Wall St. target price||$20.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.71|
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2023-01-31)||24.11%|
|1 month (2023-01-06)||92.41%|
|3 months (2022-11-07)||74.80%|
|6 months (2022-08-05)||27.10%|
|1 year (2022-02-07)||-0.75%|
|2 years (2021-02-03)||N/A|
|3 years (2020-02-03)||N/A|
|5 years (2018-02-03)||N/A|
Valuing Tyra Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tyra Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Tyra Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Tyra Biosciences shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Tyra Biosciences's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
|Gross profit TTM||$0|
|Return on assets TTM||-11.37%|
|Return on equity TTM||-18.13%|
|Market capitalisation||$365.9 million|
TTM: trailing 12 months
We're not expecting Tyra Biosciences to pay a dividend over the next 12 months.
You may also wish to consider:
Tyra Biosciences, Inc. , a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.